Update PET in der Pädiatrischen Onkologie

Roll, Wolfgang; Dirksen, Uta; Weckesser, Matthias

doi:10.1055/a-0621-3182

Cited by 1 publication

(1 citation statement)

References 75 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At the present time, there are few efficient therapeutic alternatives available for RMS patients and the only standard treatment protocol for the three subgroups of RMS including low-, intermediate-, and high-risk is the VAC-triple therapy. The VAC regimen consists of an alkylating agent such as cyclophosphamide or ifosfamide along with vincristine and dactinomycin (actinomycin-D) [5,276,277,464]. Considerable research efforts have been made to improve the treatment outcome of pediatric metastatic RMS by adding one or more anticancer compounds to the standard VAC chemotherapy; however, to date, none of the new regimes have been more effective than the VAC protocol [62].…”

Section: Discussionmentioning

confidence: 99%

Rhabdomyosarcoma: Current Therapy, Challenges, and Future Approaches to Treatment Strategies

Zarrabi,

Perrin,

Kavoosi

et al. 2023

Cancers

View full text Add to dashboard Cite

Rhabdomyosarcoma is a rare cancer arising in skeletal muscle that typically impacts children and young adults. It is a worldwide challenge in child health as treatment outcomes for metastatic and recurrent disease still pose a major concern for both basic and clinical scientists. The treatment strategies for rhabdomyosarcoma include multi-agent chemotherapies after surgical resection with or without ionization radiotherapy. In this comprehensive review, we first provide a detailed clinical understanding of rhabdomyosarcoma including its classification and subtypes, diagnosis, and treatment strategies. Later, we focus on chemotherapy strategies for this childhood sarcoma and discuss the impact of three mechanisms that are involved in the chemotherapy response including apoptosis, macro-autophagy, and the unfolded protein response. Finally, we discuss in vivo mouse and zebrafish models and in vitro three-dimensional bioengineering models of rhabdomyosarcoma to screen future therapeutic approaches and promote muscle regeneration.

show abstract